Exelixis EXEL U.S. — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's u.s. — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's U.S. — total revenues?
- Exelixis (EXEL) reported U.S. — total revenues of $558.55M in Q1 2026.
- How has Exelixis's U.S. — total revenues changed year-over-year?
- Exelixis's U.S. — total revenues increased by 8.0% year-over-year, from $517.18M to $558.55M.
- What is the long-term trend for Exelixis's U.S. — total revenues?
- Over 4 years (2021 to 2025), Exelixis's U.S. — total revenues has grown at a 18.4% compound annual growth rate (CAGR), from $1.09B to $2.14B.
- What does U.S. — total revenues mean?
- The total amount of money earned from all business activities conducted within the United States.
- How do you interpret U.S. — total revenues?
- An increase indicates successful product adoption, effective commercial execution, or expansion of the patient base, while a decrease may signal increased competition, pricing pressure, or loss of market exclusivity.
- How does U.S. — total revenues compare across companies?
- Comparable to domestic net sales or regional revenue segments reported by other mid-to-large cap biopharmaceutical companies, often benchmarked against regional market share data.